Vital Therapies eviscerated as PhIII disaster forces it to discard sole asset
Vital Therapies has built its whole operation upon the cell-based treatment for acute liver failure it calls ELAD. That foundation has now collapsed.
The San Diego-based biotech announced that ELAD failed both primary and secondary endpoints in a Phase III trial, showing no significant improvement in overall survival or proportion of survivors at study day 91 for patients with severe alcoholic hepatitis. Seeing no short path to approval, Vital has decided to “cease any further development of the ELAD System and explore strategic options.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.